Drug profile

The FDA adverse-event record for Afoxolaner, Moxidectin, Pyrantel

18 FDA reports name Afoxolaner, Moxidectin, Pyrantel, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#1884 of 2,679
by report volume (all drugs)
18
adverse-event reports
22.2%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Afoxolaner, Moxidectin, Pyrantel ranks #1884 of 2679 by total reports (18). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1884
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Afoxolaner, Moxidectin, Pyrantel has 18 reports now versus 13 in that prior snapshot: 5 more (38.5%).

Report change
+5
Death-coded reports
+0
Death-coded share
−8.5 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Afoxolaner, Moxidectin, Pyrantel changes

Signature read: Afoxolaner, Moxidectin, Pyrantel's 22.2% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
18
Total Reports
4
Deaths Reported
22.2%
Death-coded share of reports

Active Ingredients

Afoxolaner, Moxidectin, Pyrantel

Administration Routes

OralUnknown

Species Affected

Dog 18

Most Affected Breeds

Retriever - Labrador 5
Terrier - Bull - American Pit 4
Beagle 1
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1
Pointer (unspecified) 1
Hound (unspecified) 1
Crossbred Canine/dog 1
Spaniel - Springer (unspecified) 1
Cattle Dog (unspecified) 1
Terrier - Yorkshire 1

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 6
Elevated serum alkaline phosphatase (ALP) 6
Neutropenia 4
Abnormal radiograph finding 4
Elevated amylase 4
Dehydration 4
Dull 4
Lethargy (see also Central nervous system depression in Neurological) 4
Regurgitation 4
Vomiting 3
Inappetence 3
Intestinal disorder NOS 3

Outcome Breakdown

Ongoing
14 (77.8%)
Euthanized
3 (16.7%)
Died
1 (5.6%)

Afoxolaner, Moxidectin, Pyrantel: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Afoxolaner, Moxidectin, Pyrantel (#1884 of 2,679 by report volume); death-coded 22.2%. PlainBreed drug row · death-coded share stamp 22.2% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →